Skip to content

Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression

Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression : Effect of TMS on Depression, Cognitive Function, and Regional Cerebral Glucose Metabolism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01198561
Enrollment
40
Registered
2010-09-10
Start date
2006-02-28
Completion date
2016-12-31
Last updated
2015-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

repetitive Transcranial Magnetic Stimulation, Major Depressive Disorder

Brief summary

The objective of this study is to investigate the antidepressant efficacy of rTMS, and to assess cortical metabolism before and after rTMS sessions in patients with major depression. We also aimed to investigate differences between the responders and nonresponders to rTMS and what would predict clinical response to rTMS.

Detailed description

The specific aims of this study is to: (1) evaluate the antidepressant efficacy of rTMS on major depression; (2) evaluate the effects of rTMS on cognitive function in depressive patients; (3) assess the effects of rTMS on cerebral glucose metabolism in depressive patients as measured by 18FDG PET; (4) investigate the differences of the regional cerebral glucose uptake changes during rTMS between responders and nonresponders to rTMS.

Interventions

DEVICErepetitive Transcranial Magnetic Stimulation

10 times repetitive TMS, high frequency

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Twenty patients fulfilling the diagnostic criteria of major depression according to DSM IV will be enrolled in the study. * Antidepressant medication will be maintained throughout the study period.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Hamilton depression rating scale (HAM-D 17)baseline, 1, 2, and 4 weeks after TMSmeasuring instrument of severity of depressive symptoms

Countries

South Korea

Contacts

Primary ContactDoh Kwan Kim, M.D., Ph.D.
paulkim@skku.edu82-2-3410-3582

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026